Highly sensitive detection of CTLA‑4‑positive T‑cell subgroups based on nanobody and fluorescent carbon quantum dots

Wang,Wu; Hou,Xiaoqiong; Yang,Xiaomei; Liu,Aiqun; Tang,Zhuoran; Mo,Fengzhen; Yin,Shihua; Lu,Xiaoling

doi:10.3892/ol.2019.10320

Highly sensitive detection of CTLA‑4‑positive T‑cell subgroups based on nanobody and fluorescent carbon quantum dots

Authors:
- Wu Wang
- Xiaoqiong Hou
- Xiaomei Yang
- Aiqun Liu
- Zhuoran Tang
- Fengzhen Mo
- Shihua Yin
- Xiaoling Lu
View Affiliations

Affiliations: School of Basic Medicine/International Nanobody Research Center of Guangxi, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: May 6, 2019 https://doi.org/10.3892/ol.2019.10320
Pages: 109-116
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection of cytotoxic T‑lymphocyte antigen‑4‑positive (CTLA‑4+) T‑cell subgroups in peripheral blood samples and tumor tissues is of great significance. In the present study, a rapid, succinct and efficient method was designed for the detection of CTLA‑4+ human T cells using a CTLA‑4‑specific nanobody‑fluorescent carbon quantum dots complex (QDs‑Nb36). QDs‑Nb36 was used for high sensitivity detection of CTLA‑4+ T cells by flow cytometry or immumofluorescent staining. The present study demonstrated that the novel technique was more specific and effective in the detection of CTLA‑4+ T‑cell ratio in the peripheral blood and tumor tissues compared with a traditional monoclonal antibody approach. Furthermore, no significant toxicity was identified in vitro and in vivo, thus suggesting that the method may have broad applications for the detection of certain lowly expressed targets.

View Figures

View References

1	Lenschow DJ, Walunas TL and Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol. 14:233–258. 1996. View Article : Google Scholar : PubMed/NCBI
2	Teft WA, Kirchhof MG and Madrenas J: A molecular perspective of ctla-4 function. Annu Rev Immunol. 24:65–97. 2006. View Article : Google Scholar : PubMed/NCBI
3	Walker LS and Sansom DM: The emerging role of ctla4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol. 11:852–863. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wakamatsu E, Mathis D and Benoist C: Convergent and divergent effects of costimulatory molecules in conventional and regulatory CD4⁺ T cells. Proc Natl Acad Sci USA. 110:1023–1028. 2013. View Article : Google Scholar : PubMed/NCBI
5	Krummel MF and Allison JP: CD28 and ctla-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 182:459–465. 1995. View Article : Google Scholar : PubMed/NCBI
6	Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H and Fujii H: Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res. 9:4404–4408. 2003.PubMed/NCBI
7	Aggarwal S, Sharma SC and N Das S: Dynamics of regulatory T cells (Tregs) in patients with oral squamous cell carcinoma. J SurgOncol. 116:1103–1113. 2017.
8	Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM and Silva JS: Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 43:1518–1528. 2013. View Article : Google Scholar : PubMed/NCBI
9	Steeland S, Vandenbroucke RE and Libert C: Nanobodies as therapeutics: Big opportunities for small antibodies. Drug Discov Today. 21:1076–1113. 2016. View Article : Google Scholar : PubMed/NCBI
10	Wan R, Liu A1, Hou X, Lai Z, Li J, Yang N, Tan J, Mo F, Hu Z, Yang X, et al: Screening and antitumor effect of an anti-CTLA-4 nanobody. Oncol Rep. 39:511–518. 2018.PubMed/NCBI
11	Muyldermans S: Nanobodies: Natural single-domain antibodies. Annual Review of Biochemistry. 775–797. 2013. View Article : Google Scholar : PubMed/NCBI
12	Zhang M, Liu H, Chen L, Yan M, Ge L, Ge S and Yu J: A disposable electrochemiluminescence device for ultrasensitive monitoring of K562 leukemia cells based on aptamers and simpleZnO@carbon quantum dots. Biosens Bioelectron. 49:79–85. 2013. View Article : Google Scholar : PubMed/NCBI
13	Yu Y, Duan S, He J, Liang W, Su J, Zhu J, Hu N, Zhao Y and Lu X: Highly sensitive detection of leukemia cells based on aptamer and quantum dots. Oncol Rep. 36:886–892. 2016. View Article : Google Scholar : PubMed/NCBI
14	Qu K, Wang J, Ren J and Qu X: Carbon dots prepared by hydrothermal treatment of dopamine as an effective fluorescent sensing platform for the label-free detection of iron (III) ions and dopamine. Chemistry. 19:7243–7249. 2013. View Article : Google Scholar : PubMed/NCBI
15	Yang ST, Wang X, Wang H, Lu F, Luo PG, Cao L, Meziani MJ, Liu JH, Liu Y, Chen M, et al: Carbon dots as nontoxic and high-performance fluorescence imaging agents. J Phys Chem C Nanomater Interfaces. 113:18110–18114. 2009. View Article : Google Scholar : PubMed/NCBI
16	Xing Y and Rao J: Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging. Cancer Biomark. 4:307–319. 2008. View Article : Google Scholar : PubMed/NCBI
17	Peter PA, Durflinger KH, Wunderlich JR, Rosenberg SA and Dudley ME: Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother. 33:547–556. 2010. View Article : Google Scholar : PubMed/NCBI
18	Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, Robbins PF, Rosenberg SA and Dudley ME: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother. 31:742–751. 2008. View Article : Google Scholar : PubMed/NCBI
19	Zhang L, Wang Z, Lu Z, Xia K, Deng Y, Li S, Zhang C, Huang Y and He N: Synthesis of LiYF4:Yb, Erupconversion nanoparticles and its fluorescence properties. J NanosciNanotechnol. 14:4710–4713. 2014. View Article : Google Scholar
20	Heo NS, Lee SU, Rethinasabapathy M, Lee EZ, Cho HJ, Oh SY, Choe SR, Kim Y, Hong WG, Krishnan G, et al: Visible-light-driven dynamic cancer therapy and imaging using graphitic carbon nitride nanoparticles. Mater Sci Eng C Mater Biol Appl. 90:531–538. 2018. View Article : Google Scholar : PubMed/NCBI
21	Ji X, Wang H, Song B, Chu B and He Y: Silicon nanomaterials for biosensing and bioimaging analysis. Front Chem. 6:382018. View Article : Google Scholar : PubMed/NCBI
22	Lamichhane N, Udayakumar TS, D'Souza WD, Simone CB II, Raghavan SR, Polf J and Mahmood J: Liposomes: Clinical applications and potential for image-guided drug delivery. Molecules. 23:2882018. View Article : Google Scholar
23	Alivisatos P: The use of nanocrystals in biological detection. Nat Biotechnol. 22:47–52. 2004. View Article : Google Scholar : PubMed/NCBI
24	Baker M: Nanotechnology imaging probes: Smaller and more stable. Nat Methods. 7:957–962. 2010. View Article : Google Scholar
25	Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N and Hamers R: Naturally occurring antibodies devoid of light chains. Nature. 363:446–448. 1993. View Article : Google Scholar : PubMed/NCBI
26	Deffar K, Shi H, Li L, Wang X and Zhu X: Nanobodies-the new concept in antibody engineering. Afr J Biotechnol. 8:2645–2652. 2009.
27	Hisada H, Tsutsumi H, Ishida H and Hata Y: High production of llama variable heavy-chain antibody fragment (VHH) fused to various reader proteins by Aspergillusoryzae. Appl Microbiol Biotechnol. 97:761–766. 2013. View Article : Google Scholar : PubMed/NCBI